Emerging Growth Research Releases Q2:26 Quarterly Update on SBC Medical Group; Reiterates Buy Rating and Increases Price Target to $11.00

NEW YORK CITY, NY / ACCESS Newswire / August 24, 2026 / Emerging Growth Research today announced the release of its Q2:26 Quarterly Update Report on SBC Medical Group Holdings (NASDAQ:SBC), reiterating its Buy rating and increasing its 12-month price target to $11.00 from $10.00.

The Quarterly Update highlights SBC Medical Group's return to revenue growth in 2026 following the completion of pricing-related headwinds experienced during 2025, while emphasizing the Company's strong cash position, expanding clinic footprint, continued international expansion, and new AI-driven growth initiatives. Emerging Growth Research believes the Company is positioned for renewed growth following the 2025 revenue decline and remains significantly undervalued relative to its long-term earnings potential.